Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ENCORAFENIB Cause Wrong technique in product usage process? 10 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Wrong technique in product usage process have been filed in association with ENCORAFENIB (BRAFTOVI). This represents 0.1% of all adverse event reports for ENCORAFENIB.

10
Reports of Wrong technique in product usage process with ENCORAFENIB
0.1%
of all ENCORAFENIB reports
0
Deaths
6
Hospitalizations

How Dangerous Is Wrong technique in product usage process From ENCORAFENIB?

Of the 10 reports, 6 (60.0%) required hospitalization.

Is Wrong technique in product usage process Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ENCORAFENIB. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does ENCORAFENIB Cause?

Death (1,004) Off label use (989) Nausea (758) Fatigue (685) Diarrhoea (574) Neoplasm progression (548) Pyrexia (539) Product use in unapproved indication (506) Vomiting (429) Rash (414)

What Other Drugs Cause Wrong technique in product usage process?

EVOLOCUMAB (21,664) ALBUTEROL (17,114) ADALIMUMAB (11,766) PEGFILGRASTIM (10,217) ETANERCEPT (9,835) ERENUMAB-AOOE (9,359) SACUBITRIL\VALSARTAN (8,022) LEUPROLIDE (5,062) FENTANYL (2,812) SEMAGLUTIDE (2,538)

Which ENCORAFENIB Alternatives Have Lower Wrong technique in product usage process Risk?

ENCORAFENIB vs ENDOXAN ENCORAFENIB vs ENDOXAN BAXTER ENCORAFENIB vs ENDOXAN INJ ENCORAFENIB vs ENDOXAN , POUDRE POUR ENCORAFENIB vs ENFORTUMAB VEDOTIN

Related Pages

ENCORAFENIB Full Profile All Wrong technique in product usage process Reports All Drugs Causing Wrong technique in product usage process ENCORAFENIB Demographics